iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

iBio (NYSEA:IBIO) announced its Chairman & CEO, Tom Isett, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:40 p.m. Eastern Time. This virtual presentation will be broadcasted live and archived on the iBio website under the 'News & Events' section.

iBio is known for its FastPharming Manufacturing System®, focusing on sustainable, plant-based biopharmaceuticals, including treatments for cancers and infectious diseases.

News Market Reaction – IBIO

+1.17%

+1.17% Session move

In the trading session that priced this news, IBIO gained 1.17%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System^®, today announced that its Chairman & CEO, Tom Isett, will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 2:40 p.m. Eastern Time.

The presentation will be broadcast live and archived on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.

About iBio, Inc.

iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System^® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, antigens, and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering  Development Services^™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

FAQ

When will iBio present at the Oppenheimer Healthcare Conference?

iBio will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:40 p.m. Eastern Time.

Where can I watch the iBio presentation from the Oppenheimer Conference?

The presentation will be broadcast live and archived on the iBio website under 'News & Events' in the Investors section.

What is the FastPharming System® of iBio?

The FastPharming System® combines vertical farming, automated hydroponics, and novel glycosylation technologies to produce biopharmaceuticals.

What kind of diseases is iBio developing treatments for?

iBio is developing proprietary biopharmaceuticals for cancers, fibrotic diseases, and infectious diseases.